FeelFit: High-intensity Interval Training to Improve Self-reported Physical Fitness in Brain Tumor Patients: a Randomized Controlled Trial
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Brain Tumor, Primary
- Sponsor
- Amsterdam UMC, location VUmc
- Enrollment
- 36
- Locations
- 1
- Primary Endpoint
- Self-reported physical fitness
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The FeelFit study aims to assess the effectiveness of High-Intensity Interval Training (HIIT) in improving self-reported physical fitness in adult brain tumor patients during periods of stable disease, as compared to a waiting-list control group. Furthermore, several secondary and exploratory outcomes will be evaluated. The study is part of the GRIP (GuaRding quality survivorshiP) project, which aims to improve quality of life in brain tumor patients.
Investigators
Linda Douw
Principal Investigator
Amsterdam UMC, location VUmc
Eligibility Criteria
Inclusion Criteria
- •reduced self-reported physical fitness;
- •minimum age of 18 years;
- •diagnosed with a primary brain tumor;
- •stable disease, i.e. no signs of radiological or clinical tumor progression;
- •no oncological treatment for at least two months prior to inclusion;
- •able to speak, read and write in Dutch.
Exclusion Criteria
- •Karnofsky Performance Score \< 70;
- •already participated in a HIIT program \< 1 month prior;
- •contraindication of exercise.
Outcomes
Primary Outcomes
Self-reported physical fitness
Time Frame: Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up)
Self-reported physical fitness is measured using the first question of the International Fitness Scale (IFIS) on general physical fitness, on a 5-point scale where a higher score corresponds to better self-reported physical fitness.
Secondary Outcomes
- Self-reported fitness(Baseline versus post-intervention (12 weeks) and versus follow-up (12 weeks and 6 weeks follow-up))
- VO2max(Baseline versus post-intervention (12 weeks))